Anti-glycolytic drugs in the treatment of hepatocellular carcinoma: Systemic and locoregional options Review
| Authors: | Pourbaghi, M.; Haghani, L.; Zhao, K.; Karimi, A.; Marinelli, B.; Erinjeri, J. P.; Geschwind, J. F. H.; Yarmohammadi, H. |
| Review Title: | Anti-glycolytic drugs in the treatment of hepatocellular carcinoma: Systemic and locoregional options |
| Abstract: | Hepatocellular cancer (HCC) is the most common primary liver cancer and the third leading cause of cancer-related death. Locoregional therapies, including transarterial embolization (TAE: bland embolization), chemoembolization (TACE), and radioembolization, have demonstrated survival benefits when treating patients with unresectable HCC. TAE and TACE occlude the tumor's arterial supply, causing hypoxia and nutritional deprivation and ultimately resulting in tumor necrosis. Embolization blocks the aerobic metabolic pathway. However, tumors, including HCC, use the "Warburg effect" and survive hypoxia from embolization. An adaptation to hypoxia through the Warburg effect, which was first described in 1956, is when the cancer cells switch to glycolysis even in the presence of oxygen. Hence, this is also known as aerobic glycolysis. In this article, the adaptation mechanisms of HCC, including glycolysis, are discussed, and anti-glycolytic treatments, including systemic and locoregional options that have been previously reported or have the potential to be utilized in the treatment of HCC, are reviewed. |
| Journal Title: | Current Oncology |
| Volume: | 30 |
| Issue: | 7 |
| ISSN: | 1198-0052 |
| Publisher: | Multimed Inc |
| Date Published: | 2023-07-01 |
| Start Page: | 6609 |
| End Page: | 6622 |
| Language: | English |
| DOI: | 10.3390/curroncol30070485 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PMCID: | PMC10377758 |
| PUBMED: | 37504345 |
| DOI/URL: | |
| Notes: | Accession Number: 168598424 -- Entry Date: In Process -- Revision Date: 20230801 -- Publication Type: Article -- Journal Subset: Biomedical; Canada; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed -- NLM UID: 9502503. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work